ISIN | LU2207278404 |
---|---|
Valor Number | 120730677 |
Bloomberg Global ID | |
Fund Name | Kieger Impact Healthcare Fund Class A CHF (H) Accumulating |
Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fund Provider | Kieger AG |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 87.67 CHF | 04.02.2025 |
---|---|---|
Previous Price * | 87.59 CHF | 03.02.2025 |
52 Week High * | 93.16 CHF | 07.03.2024 |
52 Week Low * | 79.94 CHF | 19.12.2024 |
NAV * | 87.67 CHF | 04.02.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 78,542,647 | |
Unit/Share Assets *** | 2,907,573 | |
Trading Information SIX |
YTD Performance | +9.46% |
31.12.2024 - 04.02.2025
31.12.2024 04.02.2025 |
---|---|---|
1 month | +6.32% |
06.01.2025 - 04.02.2025
06.01.2025 04.02.2025 |
3 months | +5.04% |
04.11.2024 - 04.02.2025
04.11.2024 04.02.2025 |
6 months | +3.80% |
05.08.2024 - 04.02.2025
05.08.2024 04.02.2025 |
1 year | -1.08% |
05.02.2024 - 04.02.2025
05.02.2024 04.02.2025 |
2 years | -13.75% |
06.02.2023 - 04.02.2025
06.02.2023 04.02.2025 |
3 years | -12.33% |
31.08.2022 - 04.02.2025
31.08.2022 04.02.2025 |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Exact Sciences Corp | 3.90% | |
---|---|---|
Abbott Laboratories | 3.60% | |
Sandoz Group AG Registered Shares | 3.58% | |
BioNTech SE ADR | 3.51% | |
Amplifon SpA Az nom Post Frazionamento | 3.49% | |
DexCom Inc | 3.49% | |
Demant AS | 3.47% | |
Hikma Pharmaceuticals PLC | 3.46% | |
Novo Nordisk AS Class B | 3.45% | |
Gilead Sciences Inc | 3.45% | |
Last data update | 30.11.2024 |
TER *** | 1.27% |
---|---|
TER date *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.00% |
Ongoing Charges *** | 1.22% |
SRRI ***
|
|
SRRI date *** | 30.09.2022 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** |
Sustainable Investment |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |